Acute Calculous CholecystitisACMENCT04744441
Mortality Risk Estimation in Acute Calculous Cholecystitis: Beyond the Tokyo Guidelines
An observational study of Acute Calculous Cholecystitis, run by Hospital del Mar.
Trial summary
Acute calculous cholecystitis (ACC) is the second most frequent surgical condition in emergency departments, the complication rate of ACC is 20-55%, and the mortality rate is 0.5-15% in recent series. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Acute Calculous Cholecystitis
- What is being tested?
- CHOLECYSTECTOMY, PERCUTANEOUS CHOLECYSTOSTOMY and EXCLUSIVE ANTIBIOTICS
- Type of treatment
- Injection or infusion, Surgery or procedure
- How many people
- 963 participants
- Where
- No sites listed yet
- Study dates
- Jan 2011to Mar 2020
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: All patients admited with a diagnostic of Acute Cholecystitis in a dedicated surgical emergency unit, from January 2011 to December 2016, in a Metropolitan University Hospital in Barcelona, Spain.
Who may be able to join
- All patients were selected if they had acute cholecystitis according to the Tokyo Guidelines of 2018 (TG18) and/or received a diagnosis of ACC in the Pathology report. The study case definition was a 'Pure Acute Cholecystitis.
Who cannot join
None listed.
About this study
Acute calculous cholecystitis (ACC) is the second most frequent surgical condition in emergency departments, the complication rate of ACC is 20-55%, and the mortality rate is 0.5-15% in recent series. The Tokyo Guidelines (TG) advocate for different initial treatments of ACC with no clear evidence that all patients will benefit from them.
The objective of the study is to identify the risk factors for mortality in ACC and compare them with TG classification.
Read more
It is a retrospective cohort study conducted from January 2011 to December 2016 in a single center with a dedicated surgical emergency unit in a Metropolitan University Hospital in Barcelona, Spain. The analysis of the data was finished in March 2020.
The study candidates comprised 963 consecutive patients with a diagnosis of ACC according to the TG18 and/or received a diagnosis of ACC in the Pathology report in those that an emergent cholecystectomy was performed.
The study case definition was a 'Pure Acute Cholecystitis' (pure ACC); therefore, patients with any other concomitant diagnosis potentially influencing outcome (Postoperative cholecystitis, Acute Cholangitis, Acute Pancreatitis, Incidental Cholecystectomy, Acalculous Cholecystitis, Chronic Cholecystitis/Persistent Colic, Post-endoscopic retrograde pancreato-cholangiography, or Neoplasia) were excluded from the final analysis.
Variables:
Primary data were available from a prospective database maintained in File Maker v.12 (Mountainview, CA, USA), which included basic demographic data, type of interventions, sex, days of admission, and complications. Every record was completed by browsing the electronic patient record, adding laboratory and microbiology data, as well as antibiotic therapy, duration of procedure, additional procedures, and grade of acute cholecystitis according to the TG18 diagnostic criteria.
Preoperative comorbidities were assessed using the Charlson Comorbidity Index and surgical risk by ASA classification. The type of initial treatment was classified as Surgical Treatment (Cholecystectomy either by laparoscopy or laparotomy) or Non-Surgical Treatment, which was either percutaneous cholecystostomy or intravenous antibiotics alone.
The main outcome measure was the mortality after the diagnostic of ACC. In the patients that were discharged, 30 days after the diagnosis, if the patients was not discharged in 30 days, at any time during the same admission.
Interventions:
All patients received intravenous antibiotic therapy from the moment the diagnosis was formulated, according to a fixed protocol.
Ultrasound-guided cholecystostomy was performed percutaneously with an 8-Fr catheter (SKATER ™, Argon Medical Devices, Rochester, NY, USA) by either transhepatic or transperitoneal insertion, at the discretion of the radiologist.
Laparoscopic Cholecystectomy was performed according to the French technique using 4 trochars. The content of the gallbladder was evacuated by Veress needle puncture when necessary.
Statistical Analysis:
The normal distribution of the quantitative variables was assessed using the Kolmogorov-Smirnov test, which showed that none of the variables were normally distributed; therefore, their values were expressed as median and interquartile ranges. The Mann-Whitney U non-parametric test was used to assess the significance of differences between means.
The association between qualitative variables was assessed with the chi-square test or Fisher's exact test, as required. The increased risk of an event associated with a variable was reported as the odds ratio (OR) and 95% confidence interval (CI).
As this was a retrospective observational study and the treatment groups were markedly asymmetric, we used the propensity score matching method to select and compare two subgroups of patients evenly balanced by severity according to the TG18 criteria and by comorbidity according to the Charlson Comorbidity Index.
A model for predicting mortality was built using binomial logistic regression with stepwise progressive conditional entry and standard baseline conditions for admission and rejection of variables with significant differences in the univariate analysis. The discrimination power of the model was assessed by receiver operating characteristic (ROC) curves and was compared with the DeLong method.
Legal and Ethical considerations This study was approved by the clinical research ethical committee of the Hospital del Mar and was classified as a non-clinical trial.
- Conditions
- Acute Calculous Cholecystitis
- Being tested
- CHOLECYSTECTOMY, PERCUTANEOUS CHOLECYSTOSTOMY, EXCLUSIVE ANTIBIOTICS
- Keywords
- Emergent Cholecystectomy, Mortality in acute Cholecystitis, High Risk Patient, Morbidity in Acute Cholecystitis, Risk Factors in Acute Cholecystitis, Unfit for Surgery, Acute Cholecystitis, Acute Calculous Cholecystitis
- Medical subject headings
- Cholecystitis, Acute
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
CHOLECYSTECTOMYProcedure or surgery
Also called Surgical Treatment
Surgical treatment
PERCUTANEOUS CHOLECYSTOSTOMYProcedure or surgery
Also called Non-Surgical Treatment
Patients treated with a percutaneous cholecystostomy
EXCLUSIVE ANTIBIOTICSProcedure or surgery
Also called Non-Surgical Treatment
Patients that are treated only with i.v. antibiotics
What is being measured
The primary outcome is the main question the study is designed to answer.
To describe the mortality in patients with a diagnostic of Acute Calculous Cholecystitis.
The main outcome measure was the number of deaths after the diagnosis of Acute Calculous Cholecystitis.
In the patients that were discharged: 30 days after the diagnosis. If the patients was not discharged in 30 days, at any time during the same admission.
Measured: 2011-2016
To describe the causes of death after a diagnostic of Acute Calculous Cholecystitis
Every death after a diagnostic of Acute Calculous Cholecystitis was defined as: septic shock, heart failure, respiratory failure and/or complication of a concomitant chronic disease before the diagnostic of pure ACC.
Measured: 2011-2016
Secondary outcomes (2)
Study of the risk factors for mortality in patients with a diagnostic of Acute Calculous Cholecystitis
The association between qualitative variables was assessed with the chi-square test or Fisher's exact test, as required. The increased risk of an event associated with a variable was reported as the odds ratio (OR) and 95% confidence interval (CI).
- Demographic data (gender, age)
- Physiological parameters (Temperature, blood pressure, cardiac and respiratory rates)
- Laboratory test (Bilirubin, Creatinine, Alkaline phosphatase, Gamma-glutamyl-transpherase, Glutamil oxaloacetic transaminase, PT-INR, Lactate, WBC, Partial oxygen pressure, CRP and Platelets)
- Type of intervention and additional procedures
- Grade of severity of ACC following the TG18
- Preoperative comorbidities were assessed using the Charlson Comorbidity Index and surgical risk by ASA classification.
Measured: 2011-2016
Comparison the mortality of surgical treatment vs. non-surgical treatment
As this was a retrospective observational study and the treatment groups were markedly asymmetric, we performed a propensity score matching method to select patients with an equal morbidity according to the Charlson Comorbidity Index and TG18 Classification at the momento of the diagnostic of ACC. Then we classified the complications of each group following the Clavien-Dindo's Classification.
Measured: 2011-2016
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Feb 2021
- Study startJan 2011
- Primary completionDec 2016
- Study completionMar 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Acute Calculous CholecystitisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 963 participants (actual)
Sponsor and investigators
- Lead sponsor
- Hospital del Mar
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Ana María González Castillo, Hospital del Mar
- Investigators
- Ana María González-Castillo, M.D., Principal investigator, Hospital del Mar
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04744441
- Sponsor's protocol ID
- Mortality Estimation in ACC
- Acronym
- ACME
- Status last verified
- Feb 2021
- First submitted
- 25 Jan 2021
- Last updated
- 9 Feb 2021
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: all primary and secondary variables of anonimyzed individual data set will be provided
Publications
Gonzalez-Castillo AM, Sancho-Insenser J, De Miguel-Palacio M, Morera-Casaponsa JR, Membrilla-Fernandez E, Pons-Fragero MJ, Pera-Roman M, Grande-Posa L. Mortality risk estimation in acute calculous cholecystitis: beyond the Tokyo Guidelines. World J Emerg Surg. 2021 May 11;16(1):24. doi: 10.1186/s13017-021-00368-x.
PubMed 33975601
Study at a glance
From the registry record, last updated by the sponsor on 9 Feb 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Mortality Risk Estimation in Acute Calculous Cholecystitis: Beyond the Tokyo Guidelines
- ClinicalTrials.gov ID
- NCT04744441
- Acronym / sponsor ID
- ACME / Mortality Estimation in ACC
- Conditions
- Acute Calculous Cholecystitis
- Keywords
- Emergent Cholecystectomy, Mortality in acute Cholecystitis, High Risk Patient, Morbidity in Acute Cholecystitis, Risk Factors in Acute Cholecystitis, Unfit for Surgery, Acute Cholecystitis, Acute Calculous Cholecystitis
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 963 participants (actual)
- Lead sponsor
- Hospital del MarUniversity, hospital or other
- Study start
- Jan 2011 (actual)
- Primary completion
- Dec 2016 (actual)
- Study completion
- Mar 2020 (actual)
- First posted
- 9 Feb 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Acute calculous cholecystitis (ACC) is the second most frequent surgical condition in emergency departments, the complication rate of ACC is 20-55%, and the mortality rate is 0.5-15% in recent series. The Tokyo Guidelines (TG) advocate for different initial treatments of ACC with no clear evidence that all patients will benefit from them.
The objective of the study is to identify the risk factors for mortality in ACC and compare them with TG classification.
It is a retrospective cohort study conducted from January 2011 to December 2016 in a single center with a dedicated surgical emergency unit in a Metropolitan University Hospital in Barcelona, Spain. The analysis of the data was finished in March 2020.
The study candidates comprised 963 consecutive patients with a diagnosis of ACC according to the TG18 and/or received a diagnosis of ACC in the Pathology report in those that an emergent cholecystectomy was performed.
The study case definition was a 'Pure Acute Cholecystitis' (pure ACC); therefore, patients with any other concomitant diagnosis potentially influencing outcome (Postoperative cholecystitis, Acute Cholangitis, Acute Pancreatitis, Incidental Cholecystectomy, Acalculous Cholecystitis, Chronic Cholecystitis/Persistent Colic, Post-endoscopic retrograde pancreato-cholangiography, or Neoplasia) were excluded from the final analysis.
Variables:
Primary data were available from a prospective database maintained in File Maker v.12 (Mountainview, CA, USA), which included basic demographic data, type of interventions, sex, days of admission, and complications. Every record was completed by browsing the electronic patient record, adding laboratory and microbiology data, as well as antibiotic therapy, duration of procedure, additional procedures, and grade of acute cholecystitis according to the TG18 diagnostic criteria.
Preoperative comorbidities were assessed using the Charlson Comorbidity Index and surgical risk by ASA classification. The type of initial treatment was classified as Surgical Treatment (Cholecystectomy either by laparoscopy or laparotomy) or Non-Surgical Treatment, which was either percutaneous cholecystostomy or intravenous antibiotics alone.
The main outcome measure was the mortality after the diagnostic of ACC. In the patients that were discharged, 30 days after the diagnosis, if the patients was not discharged in 30 days, at any time during the same admission.
Interventions:
All patients received intravenous antibiotic therapy from the moment the diagnosis was formulated, according to a fixed protocol.
Ultrasound-guided cholecystostomy was performed percutaneously with an 8-Fr catheter (SKATER ™, Argon Medical Devices, Rochester, NY, USA) by either transhepatic or transperitoneal insertion, at the discretion of the radiologist.
Laparoscopic Cholecystectomy was performed according to the French technique using 4 trochars. The content of the gallbladder was evacuated by Veress needle puncture when necessary.
Statistical Analysis:
The normal distribution of the quantitative variables was assessed using the Kolmogorov-Smirnov test, which showed that none of the variables were normally distributed; therefore, their values were expressed as median and interquartile ranges. The Mann-Whitney U non-parametric test was used to assess the significance of differences between means.
The association between qualitative variables was assessed with the chi-square test or Fisher's exact test, as required. The increased risk of an event associated with a variable was reported as the odds ratio (OR) and 95% confidence interval (CI).
As this was a retrospective observational study and the treatment groups were markedly asymmetric, we used the propensity score matching method to select and compare two subgroups of patients evenly balanced by severity according to the TG18 criteria and by comorbidity according to the Charlson Comorbidity Index.
A model for predicting mortality was built using binomial logistic regression with stepwise progressive conditional entry and standard baseline conditions for admission and rejection of variables with significant differences in the univariate analysis. The discrimination power of the model was assessed by receiver operating characteristic (ROC) curves and was compared with the DeLong method.
Legal and Ethical considerations This study was approved by the clinical research ethical committee of the Hospital del Mar and was classified as a non-clinical trial.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- All patients admited with a diagnostic of Acute Cholecystitis in a dedicated surgical emergency unit, from January 2011 to December 2016, in a Metropolitan University Hospital in Barcelona, Spain.
Key inclusion criteria (1 listed)
- All patients were selected if they had acute cholecystitis according to the Tokyo Guidelines of 2018 (TG18) and/or received a diagnosis of ACC in the Pathology report. The study case definition was a 'Pure Acute Cholecystitis.
Key exclusion criteria (0 listed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| CHOLECYSTECTOMYAlso: Surgical TreatmentSurgical treatment | Procedure or surgery | – |
| PERCUTANEOUS CHOLECYSTOSTOMYAlso: Non-Surgical TreatmentPatients treated with a percutaneous cholecystostomy | Procedure or surgery | – |
| EXCLUSIVE ANTIBIOTICSAlso: Non-Surgical TreatmentPatients that are treated only with i.v. antibiotics | Procedure or surgery | – |
Primary outcome
To describe the mortality in patients with a diagnostic of Acute Calculous Cholecystitis.
Time frame: 2011-2016
The main outcome measure was the number of deaths after the diagnosis of Acute Calculous Cholecystitis. In the patients that were discharged: 30 days after the diagnosis. If the patients was not discharged in 30 days, at any time during the same admission.
To describe the causes of death after a diagnostic of Acute Calculous Cholecystitis
Time frame: 2011-2016
Every death after a diagnostic of Acute Calculous Cholecystitis was defined as: septic shock, heart failure, respiratory failure and/or complication of a concomitant chronic disease before the diagnostic of pure ACC.
2 secondary outcomes
Study of the risk factors for mortality in patients with a diagnostic of Acute Calculous Cholecystitis
Time frame: 2011-2016
Comparison the mortality of surgical treatment vs. non-surgical treatment
Time frame: 2011-2016
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Feb 2021.
- Derived from this study: PubMed 33975601Gonzalez-Castillo AM, Sancho-Insenser J, De Miguel-Palacio M, Morera-Casaponsa JR, Membrilla-Fernandez E, Pons-Fragero MJ, Pera-Roman M, Grande-Posa L. Mortality risk estimation in acute calculous cholecystitis: beyond the Tokyo Guidelines. World J Emerg Surg. 2021 May 11;16(1):24. doi: 10.1186/s13017-021-00368-x.
- Individual participant dataSharing planned: Yes. all primary and secondary variables of anonimyzed individual data set will be provided
Related trials for Acute Calculous Cholecystitis
Not yet recruitingObservational study
SnapChole: An International, Time-Bound Prospective Platform Study of Management Strategies and Outcomes in Acute Calculous Cholecystitis
Cholecystitis, Acute
Not yet recruiting
Percutaneous Drainage Versus EUS-guided Gallbladder Drainage in Poor Surgical Patients With Cholecystitis
Cholecystitis, Acute
RecruitingObservational study
Influence of Gut Microbiome in Gallstone Disease
Gall Stone, Gall Stones, Common Bile Duct
Recruiting
Repeat Biliary Point of Care Ultrasound for Detecting Early Acute Cholecystitis
Cholecystitis, Acute, Biliary Diseases
Not yet recruiting
Implementation of RICA (ERAS) Guidelines in Grade II Acute Cholecystitis Undergoing Early Laparoscopic Cholecystectomy
Cholecystitis, Acute, Cholecystectomy, Laparoscopic
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Ana María González-Castillo, M.D. principal investigator
Hospital del Mar
Questions about this trial
What is this clinical trial studying?
An observational study of Acute Calculous Cholecystitis, run by Hospital del Mar.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 9 Feb 2021. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
To describe the mortality in patients with a diagnostic of Acute Calculous Cholecystitis. (time frame: 2011-2016). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04744441, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Feb 2021.